Veterinary Recombinant Biologics
KindredBio is revolutionizing veterinary therapeutic biologics, such as monoclonal antibodies and recombinant proteins.
In humans, therapeutic biologics have revolutionized medicine, providing safe and effective treatments for many diseases, including various cancers and autoimmune disorders. KindredBio is developing next-generation veterinary therapeutic biologics — such as monoclonal antibodies and recombinant proteins — for dogs and cats.
Monoclonal antibodies (mAb) are antibodies produced by identical cells that are cloned from a unique parent cell. They bind to a specific epitope on the targeted cell type or soluble target.
Monoclonal antibodies are deemed by many to be the gold standard of treatment for many diseases because of their safety and efficacy profile as well as their high specificity and long half-life.
Recombinant biologics are produced by inserting the genetic code for a specific therapeutic protein into the DNA of an expression vector in the laboratory. The inserted DNA codes result in large quantities of recombinant protein produced through replication in living host cells.
Then we purify the recombinant protein and administer it to the animal (cat, dog, or horse) for targeted therapy. This final preparation (drug formulation) is sterile and contains a highly pure and targeted drug. One recombinant protein commonly used in human medicine is erythropoietin alpha (Epogen®).6
Watch this video to learn more about how KindredBio is a pioneer in the field of veterinary therapeutic recombinant protein technology.
US-CORP-2000010 FEB-20